MyoKardia

P/E
Net profit
P/B
Book value
Debts
Net debt
Yield
Growth potential

MyoKardia balance sheet

Report period2015 2016 2017 2018 2019 Q3 20
End date of the reporting period
Capitalization, $
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Assets
Total ordinary shares
Ordinary share price

MyoKardia cash flows

Report period2015 2016 2017 2018 2019
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

MyoKardia multipliers

Report period2015 2016 2017 2018 2019
P/E
E/P
P/B
P/S
P/FCF
L/A
Net Debt/EBITDA
EV/EBITDA

MyoKardia profitability

Report period2015 2016 2017 2018 2019
ROA
ROE
ROS
MyoKardia assets
MyoKardia cash flows
MyoKardia news
06.11.2020
The loss of MyoKardia under GAAP for 9 months of 2020 amounted to $218.197 million, which is 0.4% more compared to $217.446 million in the previous year.
Source: {source} pictogram myokardia.gcs-web.com
Pictogram next
05.10.2020
Bristol Myers Squibb purchases MyoKardia for $13.1 billion or $225.00 per share. The transaction was approved by the boards of directors of both companies and will be closed in Q4 2020.
Source: {source} pictogram news.bms.com
Pictogram next
All MyoKardia news
General information
Company nameMyoKardia
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address333 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-741-0900
Mailing address333 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Websitewww.myokardia.com
Information disclosurewww.sec.gov